Highest-materiality recent filing
BNB Plus Corp. amends Registration Rights Agreement to extend Filing Date
Amendment extends Filing Date to 30 calendar days after Final Closing Date, which must occur on or before July 17, 2026.
BNB Plus raises $4.3M via private placement of preferred stock and warrants
Closed Inducement Agreements with three investors on June 23-24, 2026, issuing 1.32M Series B-1, 1.20M Series B-2 Preferred, and warrants for 2.30M B-2 shares for $1.54M.
BNB Plus raises $2.5M via preferred stock/warrants, additional $0.22M from inducement
Closed SPA on May 28: issued 2,380,953 Series B-1 Preferred shares and Common Warrants at $1.05/share, gross proceeds $2.5M.
Initial SPA closing of $2.5M expected May 28; Series B-1 Preferred (8% dividend) and Common Warrants ($0.76 strike) issued.
BNB Plus stockholders approve reverse stock split authorization (1:5 to 1:30)
Vote: 2,420,538 for, 317,840 against, 11,866 abstained on reverse split proposal.
BNB Plus receives Nasdaq delisting notice for bid price non-compliance; ineligible for grace period
Nasdaq notified BNB Plus on March 20, 2026 that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Mar 19.
BNB Plus appoints digital asset veteran James Haft as independent director
James Haft appointed to board and Nominating Committee effective Feb 2, 2026.
Director Elizabeth M. Schmalz Shaheen resigns from BNB Plus board effective Jan. 15, 2026
Elizabeth M. Schmalz Shaheen resigned as director of BNB Plus on January 15, 2026.
BNB Plus stockholders approve increase in authorized shares to 500M and amend equity plan
Proposal to authorize exercisability of pre-funded warrants and issuance of underlying common stock passed with 1,642,390 votes for.
Applied DNA rebrands to BNB Plus Corp., appoints Josh Kruger as Board Chairman
Name changed to BNB Plus Corp. effective Nov 13, 2025; ticker remains BNBX on Nasdaq.
Applied DNA Sciences appoints Joshua Kruger as Chairman, replacing Judith Murrah
Appointment effective November 6, 2025; Kruger also becomes director, filling vacancy from Sanford Simon's resignation.
Applied DNA Sciences enters $8.16M ATM offering and consulting deal with Patrick Horsman
ATM agreement with Lucid Capital Markets for up to $8,157,932 of common stock at market prices.
Applied DNA closes $27M PIPE, buys 15,555 BNB tokens, launches digital asset treasury
Gross proceeds of ~$27M from PIPE, with potential additional $31M from warrant exercises.
Applied DNA cuts 60% of workforce ($1.4M charges), ticker changes to BNBX Oct 7
Reduces workforce by 16 employees (~60%) with estimated pre-tax charges of ~$1.4M for severance and benefits.
APDN raises $27M via PIPE for BNB treasury strategy; CEO replaced, ticker to change to BNBX
Gross proceeds ~$27M from private placement of shares & warrants; up to $58M if warrants exercised; proceeds to acquire BNB tokens.
Applied DNA Sciences raises $26.8M, appoints new CEO, adopts BNB treasury strategy
Raised approximately $26.8 million via private placement selling 4.73M shares and warrants at $3.82 per share.
Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially
Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.
Applied DNA regains Nasdaq minimum bid price compliance; hearing cancelled
On July 2, 2025, Nasdaq notified Applied DNA it regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab
Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.
Applied DNA CEO James Hayward retires; President Judy Murrah named CEO and Chair
CEO and Chairman James Hayward retires effective June 18, 2025, after 20-year tenure.
Applied DNA Sciences receives Nasdaq delisting notice for bid price deficiency; requests hearing
Nasdaq notified APDN on May 30, 2025 that bid price closed below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
Applied DNA announces 1-for-15 reverse stock split effective June 2, 2025
Reverse stock split ratio set at 1-for-15; effective 12:01 a.m. ET on June 2, 2025.
Applied DNA shareholders approve reverse split, warrant exercise, share increase at annual meeting
All six director nominees elected (Hayward, Catell, Ceccoli, Shamash, Simon, Shaheen) with average ~572K for vs ~117K withheld.
Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M
Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.
Applied DNA Sciences regains Nasdaq minimum bid price compliance
Nasdaq notified APDN on April 7, 2025 that compliance with Rule 5550(a)(2) is regained.
Applied DNA Sciences sets 2025 annual meeting for May 22; proposal deadline April 11
2025 Annual Meeting scheduled for May 22, 2025, held virtually.
Reverse split ratio 1:50; outstanding shares reduce from ~55.2M to ~1.1M.
Applied DNA Sciences special meeting fails quorum; warrant approval delayed
Reconvened special meeting on Feb 28, 2025, had only 16,413,535 shares present, short of one-third outstanding requirement.
Applied DNA fails to secure quorum at special meeting; adjourned to Feb 28
Special meeting on Feb 14, 2025 had 16,020,694 shares present, below one-third quorum requirement.
Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.
On Jan 24, 2025, Marcum resigned as auditor; Audit Committee approved engagement of CBIZ CPAs P.C. for FY ending Sep 30, 2025.
Applied DNA Sciences special meeting lacks quorum; warrant exercise approval delayed to Feb 14
Special meeting on Jan 23 lacked quorum; only 14,062,557 shares present, below one-third required.
Filing reports use of a company presentation dated January 13, 2025 for investor meetings.
Q4 revenue $813K (up vs $780K YoY); FY revenue $3.4M vs $13.4M; net loss Q4 $3.3M ($0.32/sh), FY $7.1M ($1.82/sh).
Applied DNA Sciences receives Nasdaq deficiency notice for minimum bid price non-compliance
Company's common stock closed below $1.00 for 31 consecutive business days from Sept 27 to Nov 11, 2024.
Applied DNA Sciences reduces stockholder quorum to one-third
Board adopted Certificate of Amendment to Bylaws effective November 7, 2024.
Applied DNA Sciences prices $6.5M registered direct and private placement
Gross proceeds ~$6.5M from sale of 20.3M shares (or pre-funded warrants) at $0.32 per share.
APDN shareholders approve reverse stock split authorization (1:5-1:50) and warrant exercisability
Six directors elected: Hayward (2.36M for, 0.91M withheld), Catell (2.38M for), Ceccoli (2.38M for), Shamash (2.38M for), Simon (2.38M for), Shaheen (2.38M for).
Applied DNA regains Nasdaq minimum bid price compliance; delisting risk removed
Received Nasdaq notice on Sept 17, 2024 that closing bid price was ≥$1.00 for 20 consecutive business days through Sept 16, 2024.
Applied DNA Sciences Q3 FY2024 revenue falls 72% YoY to $798K; operating loss widens
Total revenues $798K for Q3 ended June 30, 2024, down from $2.9M, driven by end of CUNY COVID testing contract.
Applied DNA Sciences special meeting fails due to lack of quorum; warrant approval deferred
Special meeting on Aug 2, 2024 had 4,056,202 shares present, below required majority; adjourned without action.
APDN receives Nasdaq delisting notice for bid price non-compliance; plans reverse split
Nasdaq notified APDN on July 12, 2024, that its common stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.
Nasdaq confirmed compliance with stockholders' equity requirement of at least $2.5M on June 27, 2024.
Applied DNA Sciences believes it regained Nasdaq minimum equity compliance after $10.8M offering
Received Nasdaq deficiency notice May 16, 2024 for stockholders' equity of -$175,385 vs. $2.5M minimum requirement.
Gross proceeds of ~$12M from 9,230,769 units at $1.30 per unit (or $1.2999 with pre-funded warrant).
Applied DNA Sciences receives Nasdaq equity deficiency notice; equity negative $175K
As of March 31, 2024, stockholders' equity was negative $175,385, below the $2.5M minimum for Nasdaq Capital Market.
Applied DNA Q2 revenue down 79% to $930k; operating loss widens to $3.6M
Total revenue $930k vs $4.4M YoY; COVID testing contract with CUNY ended June 2023.
Applied DNA provides investor presentation with no new material disclosures
Company filed a presentation for investor use; no financial results or guidance included.
Reverse stock split at 1:20 ratio approved; effective 12:01 a.m. ET on April 25, 2024.
Applied DNA to effect 1-for-20 reverse stock split on April 25, 2024 to regain Nasdaq compliance
Reverse stock split at 1:20 ratio effective 12:01 a.m. ET on April 25, 2024; shares trade split-adjusted at market open.
On June 17, 2025, the Board elected Judith Murrah, the Company’s current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025.
On June 16, 2025, Dr. James A. Hayward informed Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Company and that he will step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025.
On July 31, 2023, Scott L. Anchin, provided notice to Applied DNA Sciences, Inc. (the “Company”) of his intention not to stand for re-election as director at the Company’s upcoming annual meeting of stockholders
On July 28, 2022, John Bitzer, III, provided notice to the Board of Directors (the “Board”) of Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Board and to not stand for re-election as director at the Company’s upcoming annual meeting of stockholders (the “Annual Meeting”), currently scheduled for September 22, 2022.
Max materiality 0.90 · Median 0.60 · Most common event other_material